Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Molecular Signature Induced by HMGA1 During Lymphoid Tumorigenesis

ABSTRACT: We are exploring the molecular pathways activated during lymphoid transformation with the long term goal of developing better therapies. Our focus is the HMGA1a oncogene because our studies indicate that it plays an important role in aggressive human lymphoid leukemia and lymphoma. We have developed the transgenic mouse over-expressing HMGA1a in lymphoid cells that develop aggressive lymphoid tumors by 8-10 months with histopathologic findings resembling human T-cell acute lymphocytic leukemia. By analyzing the gene expression profiles of our HMGA1a mouse model we plan to identify molecular pathways activated by HMGA1a in lymphoid transformation. Results from these studies will enhance our understanding of the pathogenesis of lymphoid malignancies and should lead to the development of better therapies. A total of 20,669 genes represented on the Affymetrix Mouse 430 2.0 GeneChipTM array were screened with cRNA prepared from lymphoid cells of HMGA1a transgenic mice at different stages in tumorigenesis. These mice develop lymphoid tumors with complete penetrance at 8-12 months of age. We isolated RNA from splenocytes at 2 months (before tumors develop) and at 12 months (after tumors are well-established). These results were compared to splenocytes from control littermates. We used two statistical approaches to define differentially expressed genes, including a parametric (Partek genomics suite analysis) and nonparametric (CAM) approach.

ORGANISM(S): Mus musculus

SUBMITTER: Linda Resar

PROVIDER: E-GEOD-22922 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

The Molecular Signature Induced by HMGA1 During Lymphoid Tumorigenesis

Project description:We are exploring the molecular pathways activated during lymphoid transformation with the long term goal of developing better therapies. Our focus is the HMGA1a oncogene because our studies indicate that it plays an important role in aggressive human lymphoid leukemia and lymphoma. We have developed the transgenic mouse over-expressing HMGA1a in lymphoid cells that develop aggressive lymphoid tumors by 8-10 months with histopathologic findings resembling human T-cell acute lymphocytic leukemia. By analyzing the gene expression profiles of our HMGA1a mouse model we plan to identify molecular pathways activated by HMGA1a in lymphoid transformation. Results from these studies will enhance our understanding of the pathogenesis of lymphoid malignancies and should lead to the development of better therapies.

2013-01-30 | GSE22922 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [ATAC-Seq]

Project description:Purpose: Richter’s Transformation (RT) is a poorly understood and often fatal progression of chronic lymphocytic leukemia (CLL) manifesting histologically as diffuse large B-cell lymphoma. PRMT5 is implicated in lymphomagenesis, but its role in CLL or RT progression is unknown. We demonstrate herein that tumors uniformly overexpress PRMT5 in patients with progression to RT. Furthermore, mice with B-specific overexpression of hPRMT5 developed a B-lymphoid expansion with increased risk of death, and Eµ-PRMT5/TCL1 double transgenic mice uniformly developed a highly aggressive disease that histologically resembles RT; where large-scale transcriptional profiling identified unique oncogenic pathways that mediate PRMT5-driven disease progression. Taken together, the discovery that PRMT5 drives oncogenic pathways promoting RT provides a compelling rationale for clinical investigation of PRMT5 inhibitors such as PRT382 in aggressive CLL/RT cases

2022-12-07 | GSE183429 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [3_vs_6_mo_RNA-Seq]

2022-12-07 | GSE183427 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [scRNA-seq and scVDJ-seq]

2022-12-07 | GSE205704 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [scRNA-Seq]

2022-12-07 | GSE183426 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [bulk low-input RNA-Seq]

2022-12-07 | GSE183425 | GEO

tp53 deficiency causes a wide tumor spectrum and elevates embryonal rhabdomyosarcoma metastasis in zebrafish

Project description:We generated tp53 deletion mutant zebrafish that spontaneously develop malignant peripheral nerve-sheath tumors, angiosarcomas, germ cell tumors, and an aggressive Natural Killer cell leukemia not previously reported in zebrafish. Each tumor type efficiently engrafted into syngeneic recipient zebrafish and shared gene expression signatures with predicted cells of origin.

2018-09-05 | GSE109581 | GEO

Expression analysis of mouse thyroid tumors

Project description:Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer, and often derives from pre-existing well-differentiated tumors. We have engineered the first mouse model of ATC by combining in the mouse thyroid follicular cells two molecular hallmarks of human ATC: activation of PI3K (via Pten deletion) and inactivation of p53. By 9 months of age, over 75% of the compound mutant mice develop aggressive, undifferentiated thyroid tumors that evolve from pre-existing follicular hyperplasia and carcinoma. These tumors display all the features of their human counterpart, including pleomorphism, epithelial-mesenchymal transition, aneuploidy, local invasion and distant metastases. We have performed expression profiling of thyroids from control, single mutants, compound mutants, follicular tumors from Pten-/- mice, and anaplastic tumors from Pten, p53-/- mice.

2012-03-14 | E-GEOD-30427 | biostudies-arrayexpress

IL7R mutational activation can initiate Ph-like and PAX5 P80R precursor B-cell acute lymphoblastic leukemia

Project description:Interleukin-7 receptor α (encoded by IL7R) is essential for lymphoid development. Whether acute lymphoblastic leukemia (ALL)-related IL7R gain-of-function mutations can trigger leukemogenesis remains unclear. Here, we demonstrate that lymphoid-restricted mutant IL7R, expressed at physiological levels in conditional knock-in mice, establishes a pre-leukemia stage in which B-cell precursors display self-renewal ability, initiating precursor B-ALL that resembles PAX5 P80R or Ph-like human leukemia. Full transformation associates with transcriptional upregulation of oncogenes such as Myc or Bcl2, downregulation of tumor suppressors such as Ikzf1 or Arid2, and major IL-7R signaling upregulation (involving both JAK/STAT5 and PI3K/mTOR), required for leukemia cell viability. Accordingly, maximal signaling drives full penetrance and early leukemia onset in homozygous IL7R mutant animals. Notably, we identify 2 transcriptional subgroups in mouse and human Ph-like ALL, and show that dactolisib and sphingosine-kinase inhibitors are novel treatment avenues for IL-7R-related cases. Our model, a unique resource to explore the pathophysiology and therapeutic vulnerabilities of B-ALL, demonstrates that IL7R can initiate this malignancy.

2021-11-02 | PXD017147 | Pride

KMT2A oncoproteins induce epigenetic resistance to targeted therapies.

Project description:Chromosomal translocations involving the Lysine-Methyl-Tansferase-2A (KMT2A) locus generate potent oncogenes that cause highly aggressive acute leukemias KMT2A and the most frequent translocation partners encode proteins that interact with DNA to regulate developmental gene expression. KMT2A-oncogenic fusion proteins (oncoproteins) contribute to the epigenetic mechanisms that allow KMT2A-rearranged leukemias to evade targeted therapies. By profiling the oncoprotein-target sites of 34 KMT2A-rearranged leukemia samples, we find that the genomic enrichment of oncoprotein binding is highly variable between samples. At high levels of expression, the oncoproteins preferentially activate either the lymphoid or myeloid lineage program depending on the fusion partner. These fusion-partner-dependent binding sites correspond to the frequencies of each mutation in acute lymphoid leukemia versus acute myeloid leukemia. By profiling a sample that underwent a lymphoid-to-myeloid lineage switching event in response to lymphoid-directed treatment, we find the global oncoprotein levels are reduced and the oncoprotein-target gene network changes. At lower levels of expression, the oncoprotein shifts to a non-canonical regulatory program that favors the myeloid lineage, and in a subset of resistant patients, the Menin inhibitor Revumenib induces a similar response. The dynamic shifts in KMT2A oncoproteins we describe likely contribute to epigenetic resistance of KMT2A-rearranged leukemias to targeted therapies.

2024-09-27 | GSE252378 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data